Nuformix (FRA:1RT) EPS (Basic): €0.00 (TTM As of Mar. 2026)


What is Nuformix EPS (Basic)?

Nuformix FRA:1RT EPS (Basic) is €0.00 as of Mar. 2026. The stock has 1 warning sign investors should review.

Nuformix's basic earnings per share (Basic EPS) for the six months ended in Mar. 2026 was €0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00.

Nuformix's EPS (Diluted) for the six months ended in Mar. 2026 was €0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00.

Nuformix's EPS without NRI for the six months ended in Mar. 2026 was €0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Nuformix's highest 3-Year average EPS without NRI Growth Rate was 34.10% per year. The lowest was -35.70% per year. And the median was 20.60% per year.

Nuformix  (FRA:1RT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Nuformix EPS (Basic) Related Terms

Nuformix EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Nuformix's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix EPS (Basic) Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.01 0.00

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.01 0.00 0.00 0.00

Nuformix EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Nuformix's Basic EPS for the fiscal year that ended in Sep. 2025 is calculated as

Basic EPS (A: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.752-0)/1661.020
=-0.00

Nuformix's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.4-0)/2121.268
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €0.00 mean?
Nuformix (FRA:1RT) has a EPS (Basic) of €0.00 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Nuformix and its competitors.
Is Nuformix's EPS (Basic) too high?
Nuformix's current EPS (Basic) is €0.00.
How does Nuformix's EPS (Basic) compare to VRTX and REGN?
Nuformix's EPS (Basic) of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Nuformix and its competitors. Nuformix's current EPS (Basic) is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (FRA:1RT) has a current EPS (Basic) of €0.00. The current EPS (Basic) is €0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Nuformix (FRA:1RT), the current EPS (Basic) is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges NFX:UK1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.